- Cardiology 84
- Dermatology 45
- Endocrinology 33
- ENT 16
- Fertility 190
- Gastroenterology 78
- General-Medicine 81
- Gynecology 80
- Hematology 19
- Infectious-Diseases 33
- Neurology 52
- Oncology 34
- Ophthalmology 23
- Orthopedics 69
- Pediatrics 31
- Procedure 23
- Public-Health 144
- Pulmonology 59
- Radiology 8
- Urology 68
- Wellness 161
- Woman-and-child 77
- 3759
- 3.5 Minute
Intranasal Vaccine Covid-19: Benefits & Side Effects
Intranasal COVID vaccines, an alternative to conventional jabs, offer a needle-free option for individuals who may experience fear or anxiety around injections, making it a promising alternative for those seeking a more comfortable vaccination experience.
India's COVID-19 vaccine program has already protected millions of people at home and abroad. Now, with the rollout of the intranasal COVID vaccine, called iNCOVACC, the program has entered a new phase. The intranasal COVID-19 vaccine, developed by Bharat Biotech, is the world's first needleless intranasal vaccine against the virus.
What Is an Intranasal COVID Vaccine?
A nasal vaccine is a type of mucosal vaccination administered through the nose instead of an injection. It targets the respiratory tract, the primary site of entry for many respiratory viruses, including SARS-CoV-2, the virus that causes COVID-19.
How Does an Intranasal Vaccine Work?
A nasal vaccine for COVID is administered by delivering four drops into each nostril through the nose. Unlike other vaccines that primarily target the bloodstream, the nasal vaccine for COVID acts on the mucosal lining, the virus's first point of contact with the body.
This approach aims to prevent the infection from taking hold, blocking its spread. Known as "sterilizing immunity," this method effectively generates a robust immune response, particularly in the respiratory tract and nose.
Immune Response Mechanism
- Antibody production: The immune response involves creating antibodies, proteins that recognise and neutralise the virus.
- Immune cell activation: Nasal vaccines stimulate the production of other immune cells, helping to clear the virus from the body.
Broad Immune Response
An intranasal COVID vaccine stimulates a broad immune response, including:
- Neutralizing IgG
- Mucosal IgA
- T Cell Responses
Site-Specific Immunity
Immune responses at the site of infection (nasal mucosa) are crucial for blocking both infection and transmission of COVID-19.
What Are the Potential Advantages of an Intranasal Vaccine?
The nasal route for vaccination offers several benefits, including:
- Excellent potential for immune response
- Non-invasive, needle-free administration
- Ease of administration
- Elimination of needle-associated risks
- High compliance
Overall, nasal vaccines have the potential to provide a safe, effective, and convenient method for vaccinating large populations against infectious diseases.
How Effective Is an Intranasal Vaccine Compared to Other Vaccines?
Nasal vaccines have shown promising results, especially for respiratory infections like influenza and COVID-19.
- Broad Immunity: Protects against COVID-19 and prevents its spread by targeting cells in the nose and throat.
- Targeted Response: Stimulates immune cells in the mucosal membrane, providing systemic and mucosal immunity in the lungs and intestines.
- Comprehensive Protection: More effective at immunising large groups and preventing even mild symptoms.
Nasal vaccines leverage the mucosal immune system for a robust defence against respiratory infections.
Is the Intranasal Vaccine Enough to Fight Against COVID-19?
The effectiveness of a COVID-19 nasal vaccine depends on several factors:
- Vaccine properties: Specific characteristics of the vaccine.
- Clinical trial results: Outcomes from preclinical and clinical research.
- Virus strains: Prevalence of circulating strains of the virus.
- Individual factors: Age, health status, and immune response.
Continued Preventive Measures
Even after vaccination, it is vital to:
- Wear masks
- Practice physical distancing
- Frequently wash hands
These measures help enhance protection and prevent the spread of COVID-19.
What Are the Potential Side Effects of an Intranasal Vaccine?
Nasal vaccinations, like any other vaccine, may cause side effects. However, the side effects of nasal vaccines are often mild and similar to those of other vaccines. Nasal vaccinations may cause the following side effects:
It's crucial to note that these adverse effects are usually milder and temporary, lasting only a few days at most. Therefore, the advantages of vaccination usually outweigh the risks of adverse effects. If you have any concerns regarding the potential side effects of a nasal vaccine, you should talk to the doctor.
Who Shouldn't Get a COVID-19 Intranasal Vaccine?
Guidelines for COVID-19 nasal vaccines may change as new data and formulations become available. Consult your healthcare provider to determine if a nasal vaccine is appropriate for you based on your specific conditions.
Who Should Consult a Doctor?
- Severe Reactions: Individuals who have had severe adverse reactions to any ingredient in a COVID-19 vaccine or a previous dose.
- Current Symptoms: Individuals currently experiencing COVID-19 symptoms should wait until they have recovered and are out of isolation.
- Special Groups: Immunocompromised individuals, such as pregnant or breastfeeding women, may need additional consideration or precautions.
Conclusion
The nasal vaccine, called iNCOVACC, will be available in government and private hospitals. Because it eliminates needle-associated hazards and can reduce vaccine hesitancy, the nasal vaccine for COVID has the potential to revolutionise the fight against the virus and provide a major boost to India's vaccination program. With India's new weapon in the fight against COVID-19, say goodbye to needle phobia and hello to hassle-free nasal protection!
Frequently Asked Questions
iNCOVACC is a nasal vaccination developed to provide active protection against SARS-CoV-2 virus infection.
There is currently no scientific data to support the use of iNCOVACC in combination with other vaccines.
No, there is no risk of contracting COVID-19 after receiving iNCOVACC.
There is no data on the use of the iNCOVACC vaccination in pregnant women.
Individuals with immunocompromised conditions and those who use immunosuppressive drugs or therapies may be at a higher risk of severe COVID-19. However, there is currently insufficient data to confirm vaccine safety and efficacy in these populations. People who are immunocompromised may not develop a robust immunological response to COVID-19.
- Cardiology 2132
- Dermatology 168
- Endocrinology 135
- ENT 97
- Fertility 217
- Gastroenterology 232
- General 478
- General-Medicine 1685
- Gynecology 169
- Hematology 85
- Infectious-Diseases 208
- Neurology 207
- Oncology 345
- Ophthalmology 65
- Orthopedics 187
- Pediatrics 83
- Procedure 72
- Public-Health 209
- Pulmonology 126
- Radiology 13
- Second Opinion 311
- Urology 294
- Wellness 600
- Woman-and-child 447
Related Blogs
If you have any questions, please fill out the enquiry form or call us, and we will get back to you promptly.
040-68334455
